Learning outcomes
By the end of this lesson you should be able to: explain the biochemical basis of lactose intolerance and its diagnosis; describe the mechanism of the glucose-galactose malabsorption and why it is present from birth; state the mechanism and the presentation of the lipid storage diseases; interpret a plasma lipid panel and name the disorders it reveals; explain the mechanism of the lipid lowering drugs and where each acts; and connect one inherited membrane receptor defect to the disease it produces.
Prerequisites
Lessons 6 to 14, the whole of Module 2, because this lesson consolidates the whole carbohydrate, lipid and membrane content into bedside reasoning.
The big idea
The brush border of the small bowel is a biochemical machine on a surface, and every one of its enzymes can be missing. The three that produce recognisable disease are the ones whose substrates arrive in quantity every day, and the symptoms in each case are the same three: fermentation by the gut bacteria produces gas, the undigested solute draws water osmotically, and the result is bloating, cramping and diarrhoea.
| Deficiency | Enzyme lost | Substrate that accumulates | Diagnostic test |
|---|---|---|---|
| Lactose intolerance | Lactase, lost after weaning in most of the world's population | Lactose | The hydrogen breath test, or a therapeutic trial of lactose withdrawal |
| Sucrase-isomaltase deficiency | Sucrase and isomaltase, a genetic defect | Sucrose and the alpha 1,6 of starch | A sucrose breath test |
| Glucose-galactose malabsorption | The SGLT1 sodium-glucose cotransporter itself | Glucose and galactose | A stool reducing substance test in the infant |
A new onset lactose intolerance in an adult after gastroenteritis is usually temporary, while the same symptom in a middle aged adult of African or Asian ancestry is lifelong. Explain the two mechanisms.
The lipid storage diseases
| Disease | Missing enzyme | Substrate accumulated | Clinical fingerprint |
|---|---|---|---|
| Tay-Sachs disease | Hexosaminidase A | GM2 ganglioside | A startle response and a cherry red macular spot in the infant, with neurodegeneration and death by four years |
| Gaucher disease | Glucocerebrosidase | Glucocerebroside | A storage cell full of crumpled tissue paper, hepatosplenomegaly and bone pain |
| Fabry disease | Alpha-galactosidase A | Globotriaosylceramide | Angiokeratomas, acroparaesthesia and renal failure in adulthood |
| Niemann-Pick disease | Sphingomyelinase | Sphingomyelin | A hepatosplenomegaly and a neurodegenerative course in the infant |
| Hurler syndrome | Alpha-L-iduronidase | Dermatan and heparan sulfate | Coarse features, corneal clouding, joint contractures |
| Hunter syndrome | Iduronate sulfatase | Dermatan and heparan sulfate | Similar but without corneal clouding, and a milder course |
NoteThe pattern of these diseases is the most powerful argument in biochemistry: a single gene, a single missing enzyme, and a recognisable disease. Enzyme replacement therapy now exists for Gaucher and Fabry, and the principle — supply the missing enzyme — is the direct application of understanding the pathway.
The plasma lipid panel
The lipid panel is the single commonest investigation in cardiovascular medicine, and every figure it reports is a lipoprotein fraction. Read it in four parts.
| Measurement | What it is | Target or range |
|---|---|---|
| Total cholesterol | All the cholesterol in every lipoprotein combined | Below about 5 mmol/L in a low risk patient |
| HDL cholesterol | The cholesterol of the reverse transport particles | Above about 1 mmol/L in a man and 1.2 in a woman |
| LDL cholesterol | The cholesterol of the delivery particles, usually calculated rather than measured | Depends on risk; below about 2.6 mmol/L in low risk and 1.8 in established disease |
| Triglyceride | The triacylglycerol of VLDL and of chylomicrons | Below about 1.7 mmol/L fasting |
The panel is drawn fasting for one reason only: a recent fatty meal loads the blood with chylomicrons, and the triacylglycerol figure becomes meaningless. Fasting for about twelve hours lets the chylomicrons clear, so that what is left is the fasting profile of endogenous production.
Watch outA triglyceride over about 10 mmol/L carries an acute risk of pancreatitis, not just of coronary disease, and it is the one lipid abnormality that is an emergency in its own right. It is also the one that responds dramatically to a very low fat diet, because the substrate is the load the lipoprotein lipase must unload.
The lipid lowering drugs
| Drug | Target | Effect on the panel | Principal adverse effect |
|---|---|---|---|
| Statins | The committed enzyme of cholesterol synthesis in the liver | LDL falls, sometimes by over half; HDL may rise slightly | Myopathy, and a transaminitis; they are the drugs with the strongest outcome evidence |
| Ezetimibe | The intestinal cholesterol transporter | A small additional LDL fall, by blocking absorption | Few, and it is used when a statin alone is insufficient |
| Bile acid sequestrants | Bind bile acids in the gut and interrupt their reabsorption | The liver diverts cholesterol into new bile acids synthesis, and LDL falls | Constipation, and impaired absorption of fat-soluble vitamins and of other drugs |
| PCSK9 inhibitors | Antibody against the protein that degrades the LDL receptor | A very large LDL fall, because the receptors are not destroyed | Injection site reactions |
| Fibrates | The peroxisome proliferator activated receptor alpha | Triglyceride falls substantially and HDL rises | Myopathy, particularly with a statin |
| Omega-3 fatty acids | Reduce hepatic triacylglycerol secretion | Triglyceride falls | Few |
A patient's LDL cholesterol falls by 55 per cent on a statin and a further 20 per cent when ezetimibe is added. Explain the two mechanisms, and why the addition works even though the statin is already maximal.
Common mistakes
Watch outSaying the HDL cholesterol in the panel is the cholesterol carried in the HDL of the blood only. HDL is the smallest and densest particle, so its cholesterol is a small fraction of the total — which is why a very high total cholesterol with a high HDL can still be a low risk patient.
Watch outSaying a lipid panel is valid after a meal. It is drawn fasting, because a recent meal loads chylomicrons and distorts the triglyceride figure entirely.
Watch outConfusing lactose intolerance with a milk allergy. Intolerance is an enzyme deficiency with no immune involvement and cannot cause hives or anaphylaxis; allergy is an IgE mediated reaction that can be life threatening.
Check your understanding
Why does a lactase deficient patient's diarrhoea improve after avoiding dairy, and why is a yoghurt better tolerated than milk?
Give the mechanism of Tay-Sachs disease and the organelle in which the substrate accumulates.
How does a bile acid sequestrant lower LDL cholesterol, and why does it interfere with the absorption of fat-soluble vitamins?
Multiple choice
Which enzyme is deficient in the commonest form of lactose intolerance?
Which organelle accumulates the undegraded substrate in a lysosomal storage disease?
Which statement about a fasting lipid panel is correct?
How do the statins lower LDL cholesterol?
Which lipid abnormality is an acute risk of pancreatitis?
Which statement about the two lipid disorders is correct?
Summary and next
The brush border of the small bowel is a surface on which the terminal steps of digestion occur, and losing one of its enzymes gives a recognisable syndrome of fermentation and osmotic diarrhoea. The lysosomal storage diseases are the same principle one organelle away: a single missing lysosomal enzyme and its substrate accumulating, and they can now be treated by supplying the enzyme that should have been there. The plasma lipid panel reports four lipoprotein fractions, it is drawn fasting because chylomicrons invalidate it, and the lipid lowering drugs pair agents that act at different points of the body's cholesterol balance.
That completes Module 2 of the biochemistry course: the carbohydrates, the lipids, the membranes they build, the vitamins and trace elements the enzymes of metabolism require, and the messengers derived from the lipids themselves. The next module turns to metabolism and energy, where the same molecules are finally burned.